BRCA2 and primary biliary cholangitis: In the baseline analyses, RRSO was not statistically significantly associated with a reduction in the risk of PBC in BRCA1 and BRCA2 carriers combined (RR 0.84, 95%CI 0.59–1.21) or the risk of CBC in BRCA1 and BRCA2 carriers combined (RR 0.95, 95%CI 0.65–1.39).